Aoxing Pharmaceutical Company Inc (AOXG) Fair Value & Analysis
Financial Services · US · Market cap $1.5M
Aoxing Pharmaceutical Company Inc
AOXG · US
Fair value as of: Aug 13, 2026
From 7 valuation models · updated 4 days ago
Share price −40.0% over the past month.
Below-average quality, screening 43% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (32/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case ($0.0030). The market is more pessimistic than our downside scenario.
- For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $0.0001 – $0.0790 · the $0.0021 price screens below the $0.0030 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Aoxing Pharmaceutical Company Inc (AOXG) currently trades at $0.0021, while our model-based Fair Value estimate is $0.0030, implying the stock looks roughly 42.9% undervalued today. The Quality Score stands at 32/100 (below-average quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Aoxing Pharmaceutical Company Inc generated revenue of $30.1M at a net margin of -4.9%. Revenue declined 13.1% year over year. It earns a return on equity of -7.6%. Net debt stands at $18.6M. Fundamentals as of Aug 13, 2026
For context, the median of 10 Financial Services peers we cover trades at -61% fair-value upside, at 43%, AOXG screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 7 models by family
Widest divergence: Multiples ($0.0600) versus Earnings-Based ($0.0100). Highest evidence: Growth-Adj P/E (68).
Notify me when AOXG reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 36 · Market factors (momentum, volatility) 17
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China.
Full company description
Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. was incorporated in 1996 and is based in Foster City, California.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2012 – FY2025 · reported fiscal years
Aoxing Pharmaceutical Company Inc reported revenue of $32.3M in FY2016 versus $8.1M in FY2012, a compound +41.2%/yr. Reported net income was $55.2K in FY2025.
Watch AOXG: get an alert when its fair value changes →
Peer Group
Shell Companies · 87 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Shell Companies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Shell Companies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Coca-Cola Company COLA | C$30.34 | C$10.62 | -65% |
| Lionheart III Corp LION | $11.73 | $18.15 | +55% |
| Agriculture & Natural Solutions Acquisition Corporation ANSC | $11.46 | $4.13 | -64% |
| AA Mission Acquisition Corp AAM | $0.0390 | $0.0394 | +1% |
| GP-Act III Acquisition Corp GPAT | $11.16 | $4.30 | -61% |
| Berto Acquisition Corp TACO | $10.45 | $2.73 | -74% |
| Axiom Intelligence Acquisition Corp AXIN | $10.29 | $1.46 | -86% |
| Bold Eagle Acquisition Corp BEAG | $10.75 | $4.00 | -63% |
| Lionheart Holdings CUB | $10.88 | $5.06 | -53% |
| Translational Development Acquisition Corp TDAC | $10.85 | $4.28 | -61% |
Compare Aoxing Pharmaceutical Company Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is Aoxing Pharmaceutical Company Inc (AOXG) overvalued or undervalued?
What is the fair value of AOXG?
What is the quality score of AOXG?
What is the revenue of Aoxing Pharmaceutical Company Inc (AOXG)?
What is the net profit margin of AOXG?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Aoxing Pharmaceutical Company Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.